Shanghai Sundise Traditional Chinese Medicine Co., Ltd.   Report issue

For profit Phase 2
Founded: Shanghai China (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2010
NCT00854087
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

fuzhenghuayu (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1